🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Follicular Lymphoma and Marginal Zone Lymphoma

Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites📍 Boston📍 New York📍 Columbus Reid Merryman, MD · Tests: Zanubrutinib, Rituximab, Epcoritamab Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Exercise, Diet Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma NCT04491370Phase 1, Phase 21 site📍 Valhalla New York Medical College · Tests: Polatuzumab vedotin Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Tafasitamab, Rituximab, Lenalidomide Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286Phase 3171 sites📍 Los Angeles📍 Plantation📍 Indianapolis Regeneron Pharmaceuticals · Tests: Odronextamab, Lenalidomide, Rituximab Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) NCT04110301Phase 1, Phase 21 site📍 Beijing Beijing Mabworks Biotech Co., Ltd. · Tests: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies NCT06191887Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen REal World Data in LYmphoma and Survival in Adults NCT03869619n/a37 sites📍 Arras📍 Besançon📍 Bordeaux Hospices Civils de Lyon · Tests: Real-life epidemiological platform of lymphoma in France Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502Phase 23 sites📍 New Haven📍 New Brunswick📍 Providence Brown University · Tests: Mosunetuzumab, Lenalidomide Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745Phase 14 sites📍 Durham📍 Cincinnati📍 Columbus Newave Pharmaceutical Inc · Tests: LP-168, LP-168 Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas NCT06350318Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Zanubrutinib, Rituximab Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas NCT04883437Phase 21 site📍 Atlanta Emory University · Tests: Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma NCT04669171Phase 1, Phase 212 sites📍 Boston📍 Rochester📍 Rochester Enterome · Tests: EO2463, lenalidomide, rituximab AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363Phase 113 sites📍 Orange📍 Miami Beach📍 Tampa Carna Biosciences, Inc. · Tests: Docirbrutinib A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716Phase 1, Phase 2114 sites📍 Birmingham📍 Phoenix📍 Scottsdale BeOne Medicines · Tests: Tacabrutideg
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy